Janus Henderson Group PLC Schedule 13G passive stakes

Janus Henderson Group Ltd. has disclosed beneficial ownership of 5,909,184 shares, representing 9.7% of Mirum Pharmaceuticals, Inc.'s common stock, as of June 30, 2026.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Forte Biosciences, Inc., reporting a 9.3% stake as of June 30, 2026.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 1,359,514 shares, representing 6.9% of the outstanding common stock of Assembly Biosciences, Inc.

Janus Henderson Group Ltd. has amended its Schedule 13G filing, reporting a decrease in its beneficial ownership of Tarsus Pharmaceuticals, Inc. common stock to 6.5%.

Janus Henderson Group Ltd. has disclosed a beneficial ownership of 7.3% of Dyne Therapeutics Inc.'s common stock as of June 30, 2026.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Protara Therapeutics, Inc., reporting a 8.4% stake as of June 30, 2026.

Janus Henderson Group Ltd. has filed a Schedule 13G, reporting beneficial ownership of 3,587,806 shares, representing 9.7% of Ziff Davis, Inc.'s common stock.

Janus Henderson Group Ltd. has amended its Schedule 13G filing, reporting a decrease in its beneficial ownership of ICU Medical, Inc. common stock to 11.1%.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 9,783,192 shares, representing 14.0% of Immix Biopharma, Inc.'s common stock, through various asset managers.

Janus Henderson Group Ltd. has updated its Schedule 13G filing to report a 0.3% beneficial ownership stake in Janux Therapeutics, Inc., indicating no change in control or significant strategic involvement.

Janus Henderson Group Ltd. has filed a Schedule 13G, disclosing a beneficial ownership of 3.8% in Flex Ltd. ordinary shares as of June 30, 2026.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 4.8% of Bicara Therapeutics Inc. common stock, as of June 30, 2026.

Janus Henderson Group Ltd. has filed a Schedule 13G, reporting beneficial ownership of 590,030 shares, representing 4.8% of Bel Fuse Inc.'s Class B Common Stock.

Janus Henderson Group Ltd. has disclosed a beneficial ownership of 3.0% in Ocugen, Inc., holding 10,000,000 shares and warrants.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 5.1% of Revolution Medicines, Inc. common stock as of June 30, 2026.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Achieve Life Sciences, Inc., reporting a 5.4% stake.

Janus Henderson Group Ltd. has reported beneficial ownership of 5.0% of Inspired Entertainment, Inc.'s common stock as of June 30, 2026, through various managed portfolios.

Janus Henderson Group Ltd. has reported beneficial ownership of 5.3% of LPL Financial Holdings Inc. common stock as of June 30, 2026.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for OSI Systems, Inc., reporting a 5.5% stake.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 500,000 ordinary shares, representing 6.2% of the class, in JATT II Acquisition Corp.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Vaxcyte, Inc., reporting a 12.1% stake.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 9.99% of Yarrow Bioscience, Inc.'s common stock, holding 266,712 shares and pre-funded warrants.

Janus Henderson Group Ltd. has filed an amendment to its Schedule 13G, reporting a decrease in its beneficial ownership of Vaxcyte, Inc. common stock.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Forte Biosciences, Inc., reporting a 2.5% stake.

Janus Henderson Group Ltd. has reported beneficial ownership of 17.1% of Class I Shares in the Privacore VPC Asset Backed Credit Fund.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 2,800,000 Class I Shares, representing 46.8% of the outstanding shares, in the Privacore PCAAM Alternative Growth Fund.

Janus Henderson Group Ltd. has reported beneficial ownership of 2,520,000 Class I Shares in Privacore PCAAM Alternative Income Fund, representing 67.4% of the class.

Janus Henderson Group Ltd. has reported beneficial ownership of 5.7% of Biohaven Ltd. common shares as of June 30, 2026.

Janus Henderson Group Ltd. has reported beneficial ownership of 10.6% of Jade Biosciences, Inc. common stock, totaling 6,273,262 shares, as of June 30, 2026.

Janus Henderson Group plc has filed a Schedule 13G reporting beneficial ownership of 9.99% of Cellectar Biosciences, Inc. common stock.